Core Insights - The company reported a total revenue of 326 million yuan for Q3 2025, with a net profit attributable to shareholders of 102 million yuan and a net cash inflow from operating activities of 104 million yuan [1]. Financial Performance - The latest debt-to-asset ratio stands at 9.06%, which is an increase of 0.11 percentage points from the previous quarter [3]. - The gross profit margin is reported at 66.86% [3]. - The return on equity (ROE) is 6.16% [3]. - The diluted earnings per share (EPS) is 1.07 yuan [3]. - The total asset turnover ratio is 0.18 times, while the inventory turnover ratio is 2.56 times [3]. Shareholder Information - The number of shareholders is 8,098, with the top ten shareholders holding a total of 66.35 million shares, accounting for 69.28% of the total share capital [3]. - The top shareholders include: - Wang Zhiyu: 39.4% - Hu Ping: 16.4% - Nanjing Zhida Venture Capital Center (Limited Partnership): 8.15% - Shenzhen Yanghe Biomedical Industry Investment Co., Ltd.: 1.18% - Feng Lixia: 0.93% - Zhao Guangming: 0.78% - Shen Tao: 0.74% - Hu Jun: 0.58% - Yu Fenghua: 0.57% - Fan Lili: 0.49% [3].

Core Insights - Weisi Medical achieved a revenue of 326 million yuan in the first three quarters of 2025, representing a year-on-year growth of 11.58% [1] - The net profit attributable to shareholders reached 102 million yuan, with a year-on-year increase of 30.68% [1] - Operating cash flow net amount was 104 million yuan, showing a significant year-on-year growth of 69.02% [1] Quarterly Performance - In Q3 2025, Weisi Medical reported a revenue of 115 million yuan, reflecting a year-on-year growth of 14.87% [1] - The net profit attributable to shareholders for the quarter was 32.82 million yuan, with a year-on-year increase of 14.99% [1] - The operating cash flow net amount for Q3 was 39.62 million yuan, marking a year-on-year growth of 33.74% [1] Company Strategy and Technology - Weisi Medical is recognized as a national-level "specialized and innovative" small giant enterprise, leveraging six core technology platforms: magnetic stimulation, electrical stimulation, electrophysiology, robotics, laser, and radiofrequency [1] - The company focuses on three strategic areas: brain-computer interfaces, rehabilitation robots, and AI healthcare, aiming to create a new rehabilitation medical system that is precise, intelligent, and closed-loop [1] - Weisi Medical is committed to driving technological upgrades in the industry and transforming clinical paradigms through a comprehensive "diagnosis-treatment-rehabilitation" cycle [1] International Expansion - The company is accelerating its internationalization efforts by actively participating in international exhibitions and receiving positive market feedback [2] - With ongoing breakthroughs in product qualification for overseas markets, international business is expected to become a new growth engine for the company's performance in the medium to long term [2]

Core Insights - Weisi Medical (688580) reported a revenue of approximately 326 million yuan for the first three quarters of 2025, representing a year-on-year increase of 11.58% [1] - The net profit attributable to the company reached 102 million yuan, marking a year-on-year growth of 30.68% [1] - The company attributed the performance improvement primarily to increased sales revenue and profit [1]

Core Viewpoint - Weisi Medical announced the approval of a stock incentive plan, granting restricted stocks to two incentive targets at a price of 22 yuan per share, with a total of 12,000 shares to be awarded on October 22, 2025 [2] Group 1 - The fourth meeting of the fourth board of directors will be held on October 22, 2025 [2] - The stock incentive plan includes a reserved grant date of October 22, 2025 [2] - The company will grant 12,000 restricted stocks to two incentive targets [2]

Core Insights - The company reported a revenue of 115,076,927.51 yuan for the third quarter of 2025, representing a year-on-year growth of 14.87% [2] - The net profit attributable to shareholders of the listed company was 32,824,044.72 yuan, showing a year-on-year increase of 14.99% [2] Financial Performance - Revenue for Q3 2025: 115.08 million yuan, up 14.87% year-on-year [2] - Net profit for Q3 2025: 32.82 million yuan, up 14.99% year-on-year [2]

Core Viewpoint - Weisi Medical (688580.SH) reported a revenue of 326 million yuan for the first three quarters, reflecting a year-on-year growth of 11.58% [1] - The net profit attributable to shareholders reached 102 million yuan, marking a year-on-year increase of 30.68% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 93.6 million yuan, up by 37.35% year-on-year [1] - The basic earnings per share stood at 1.07 yuan [1] Financial Performance - Revenue for the first three quarters: 326 million yuan, up 11.58% year-on-year [1] - Net profit attributable to shareholders: 102 million yuan, up 30.68% year-on-year [1] - Net profit after non-recurring items: 93.6 million yuan, up 37.35% year-on-year [1] - Basic earnings per share: 1.07 yuan [1]

Core Viewpoint - Weisi Medical reported a revenue of 115 million yuan for Q3 2025, marking a year-on-year increase of 14.87% and a net profit attributable to shareholders of 32.824 million yuan, up 14.99% [1] Financial Performance - For the first three quarters, the company achieved a revenue of 326 million yuan, reflecting a year-on-year growth of 11.58% [1] - The net profit attributable to shareholders for the same period reached 102 million yuan, showing a significant year-on-year increase of 30.68% [1] - Basic earnings per share for Q3 2025 were reported at 0.35 yuan [1]

南京伟思医疗科技股份有限公司 3、最近 12 个月内因重大违法违规行为被中国证监会及其派出机构行政处罚或 者采取市场禁入措施； 4、具有《公司法》规定的不得担任公司董事、高级管理人员情形的； 5、法律法规规定不得参与上市公司股权激励的； 董事会薪酬与考核委员会 关于 2025 年限制性股票激励计划预留授予激励对象名单 的核查意见（截至授予日） 南京伟思医疗科技股份有限公司（以下简称"公司"）董事会薪酬与考核委员 会依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办 法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、《科创 板上市公司自律监管指南第 4 号——股权激励信息披露》等相关法律、法规及规范 性文件和《南京伟思医疗科技股份有限公司章程》（以下简称"《公司章程》"）的有 关规定，对公司 2025 年限制性股票激励计划（以下简称"本激励计划"）预留授予 激励对象名单（截至授予日）进行了核查，发表核查意见如下： （一）本激励计划预留授予激励对象均不存在《管理办法》第八条规定的不 ...

| 激励对象类别 | 获授的限制性 股票数量（万 | 占本激励计 划拟授出权 | 占预留授予 日公司股本 | | --- | --- | --- | --- | | | 股） | 益数量的比 例 | 总额的比例 | | 董事会认为需要激励的其他人员（2 人） | 1.2 | 1.24% | 0.013% | | 合计 | 1.2 | 1.24% | 0.013% | 注：上表中部分合计数与各明细数相加之和在尾数上如有差异，系以上百分比结果四舍五入所致。 （1）公司全部在有效期内的股权激励计划所涉及的标的股票总数累计未超过 公司股本总额的 20.00%。上述任何一名激励对象通过全部在有效期内的股权激励 计划获授的公司股票数量累计未超过公司股本总额的 1.00%。 南京伟思医疗科技股份有限公司 2025 年限制性股票激励计划预留授予激励对象名单 （截至授予日） 一、 公司 2025 年限制性股票激励计划（以下简称"本激励计划"）的分配情况 （2）以上激励对象不包括公司独立董事、监事以及外籍员工。 南京伟思医疗科技股份有限公司董事会 2025 年 10 月 22 日 1 ...

证券代码：688580 证券简称：伟思医疗 公告编号：2025-040 南京伟思医疗科技股份有限公司 关于向激励对象授予预留部分限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 限制性股票预留授予日：2025 年 10 月 22 日 限制性股票预留授予数量：1.2 万股，占目前公司股本总额 9,577.1288 万股的 0.013% 股权激励方式：第二类限制性股票 《南京伟思医疗科技股份有限公司 2025 年限制性股票激励计划（草案）》 （以下简称"《激励计划》"）规定的授予条件已经成就，根据南京伟思医疗科 技股份有限公司（以下简称"公司"）2024 年年度股东大会授权，公司于 2025 年 10 月 22 日召开第四届董事会第六次会议，审议通过了《关于向激励对象授予 预留部分限制性股票的议案》，确定 2025 年 10 月 22 日为公司 2025 年限制性股 票激励计划（以下简称"激励计划"或"本激励计划"）预留授予日，以 22 元/ 股的授予价格向2名激励对象授予1.2万股限制性股票。 ...